Levosimendan Bioglan (Levosimendan)

• Levosimendan is employed in the management of acute cardiac failure states where enhanced contractility and vasodilation are required.
• Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion, helping stabilize patients awaiting further therapy.
• Cardiogenic shock: provides inotropic support while lowering systemic vascular resistance, facilitating blood pressure recovery in critically ill patients.
• Low‑output heart failure after cardiac surgery: stabilizes hemodynamics and may aid weaning from mechanical circulatory support.

• Levosimendan binds to cardiac troponin C in a calcium‑dependent manner, increasing the sensitivity of the contractile apparatus to existing intracellular calcium without raising calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing peripheral vasodilation and reducing afterload. These combined actions enhance myocardial contractility while improving systemic circulation. The drug’s effect is independent of β‑adrenergic receptors, allowing use in patients receiving β‑blockade.

Levosimendan may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypotension: drop in blood pressure due to vasodilation.
• Headache: mild to moderate cephalic discomfort.
• Nausea: gastrointestinal upset.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
• Severe hypotension: profound blood pressure fall requiring intervention.

When using Levosimendan, clinicians should consider several precautionary measures to minimize risk.

• Cardiac arrhythmias: monitor ECG continuously for new or worsening arrhythmias.
• Hypotension: assess blood pressure before and during infusion; adjust dose if needed.
• Renal impairment: use with caution in patients with reduced renal function, as clearance may be affected.
• Hepatic dysfunction: dose adjustment may be required in severe liver disease.
• Pregnancy and lactation: safety not established; avoid use unless benefit outweighs potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant vasodilators (e.g., nitroglycerin): may cause severe hypotension.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase levosimendan plasma levels.
• Other inotropes (e.g., dobutamine, milrinone): risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt the inotropic response.
• Diuretics: can exacerbate hypotension if volume depletion occurs.
• ACE inhibitors or ARBs: additive blood pressure‑lowering effect.
• Calcium channel blockers: may affect vascular tone and interact with potassium channel activity.